-
Parasite Inhibitor
Fenbendazole analog-1 is an antiparasitic compound that functions by inhibiting rat brain tubulin polymerization. This analog demonstrates significant activity against the protozoa Giardia lamblia and Entamoeba histolytica, as well as the helminth Trichinella spiralis. It serves as a valuable tool for studies focused on parasitic infections and tubulin-targeting therapies. -
Parasite Inhibitor
Dodecamethylpentasiloxane acts as a parasite inhibitor, showcasing insecticidal properties specifically against bed bugs. This siloxane compound is utilized in various applications due to its effectiveness in pest management and control. Its unique chemical structure allows it to disrupt the physiological processes of target organisms, making it a valuable reagent in research focused on overcoming insect infestations. -
Parasite Inhibitor
Arprinocid, a purine analog, selectively targets and inhibits the growth of the parasite Toxoplasma gondii in murine models. Its unique mechanism of action interferes with nucleotide metabolism, thereby exhibiting significant antiparasitic activity. This compound is valuable for research applications focused on the pathogenesis and treatment of Toxoplasmosis. -
Parasite Inhibitor
D-Phenothrin is a synthetic pyrethroid classified as a Type II insecticide, primarily targeting insect nervous systems. It exhibits potent insecticidal activity against a variety of pests, including mosquitoes and human lice, making it valuable in both agricultural and veterinary settings. This compound is extensively utilized for pest control in crops and animal husbandry, contributing to effective vector management and enhancing public health. -
Parasite Inhibitor
Tectol is a farnesyltransferase inhibitor, effectively targeting the enzyme in both human and Trypanosoma brucei systems. With IC50 values of 2.09 μM and 1.73 μM respectively, Tectol demonstrates potent antitumor activity against human leukemia cell lines HL60 and CEM. In addition, it exhibits significant inhibitory effects on the drug-resistant strain of Plasmodium falciparum (FcB1), with an IC50 of 3.44 μM, making it a valuable tool for researching parasitic and cancer biology. -
PfGSK3/PfPK6 Inhibitor
PfGSK3/PfPK6-IN-1 is a selective inhibitor targeting PfGSK3 and PfPK6, with IC50 values of 97 nM and 8 nM, respectively. This compound effectively inhibits the proliferation of blood-stage Plasmodium falciparum 3D7 parasites, making it a valuable tool for malaria research. Additionally, PfGSK3/PfPK6-IN-1 exhibits low cytotoxicity in hepatocyte cultures at concentrations up to 200 nM, with a significant reduction in cell viability observed at 2 μM. Its dual action enhances its potential in studying malaria-related mechanisms and potential therapeutic strategies. -
Parasite Inhibitor
Melarsonyl, also known as Melarsonic acid, is an anthelmintic agent that targets and inhibits parasitic organisms. It exhibits potent activity against a variety of parasites, making it valuable in research aimed at understanding and combating parasitic infections. This compound is utilized in the study of helminthic diseases and other related areas in parasitology. -
Parasite Inhibitor
Piperazine adipate is an effective anthelmintic agent that targets parasitic worms in mammals. Its broad-spectrum activity makes it suitable for treating various helminth infections, thereby providing significant therapeutic benefits in veterinary and clinical settings. This compound is utilized in research to explore mechanisms of helminth resistance and to develop novel treatment protocols against parasitic infections. -
Parasite Inhibitor
Phosalone is an organophosphate insecticide that primarily targets acetylcholinesterase, leading to the inhibition of neurotransmission in parasites. Its potent biological activity makes it effective in controlling a wide range of insect pests. Phosalone is utilized in entomological research and in studies focusing on pest management strategies and the biochemical pathways of insecticide resistance. -
Parasite Inhibitor
trans-Permethrin is a synthetic pyrethroid that primarily targets the nervous system of insects, functioning as a potent insecticide and neurotoxin. Its primary biological activity involves disrupting sodium channel function, leading to paralysis and death in targeted pest populations. This compound is widely used in research applications aimed at understanding insecticide resistance mechanisms and developing novel pest control strategies. -
Parasite Inhibitor
Bitoscanate, also known as p-Phenylene diisothiocyanate, primarily acts as a parasite inhibitor. It demonstrates significant activity against hookworms, making it valuable in the therapeutic management of parasitic infections. Its biological properties facilitate research applications focused on developing effective treatments for helminthic diseases. -
Parasite Inhibitor
CWHM-1552 is a potent inhibitor of Plasmodium falciparum, demonstrating IC50 values of 51 nM and 53 nM against the 3D7 and Dd2 strains, respectively. This compound exhibits significant efficacy in oral administration and is designed for research applications focused on malaria treatment and parasite biology. CWHM-1552 serves as a valuable tool for studying antimalarial mechanisms and developing novel therapeutic strategies. -
Parasite Inhibitor
Anticancer agent 140 is a compound designed as a parasite inhibitor, exhibiting significant potential for anticancer and antiparasitic activities. This reagent targets specific cellular pathways, making it valuable for research in cancer biology and parasitology. Its effectiveness in inhibiting parasite proliferation underscores its relevance in drug discovery and development for related diseases. -
Parasite Inhibitor
Mirincamycin hydrochloride is a potent inhibitor of malaria, specifically targeting the early liver stages of Plasmodium. This compound demonstrates protective effects, effectively preventing the progression of the parasite during its initial infection phase. However, it is important to note that Mirincamycin does not eliminate dormant liver stages, as observed in studies utilizing a rhesus monkey model. This characteristic limits its applicability in certain therapeutic scenarios against malaria. -
Parasite Inhibitor
Allylpyrocatechol is a parasite inhibitor known for its antimalarial activity. This compound has been validated for its efficacy both in vitro and in vivo, demonstrating significant potential in combating malaria. Additionally, structure-activity relationship analyses of its analogs have been conducted, providing insights into the mechanisms underlying its biological effects. Its application in research can contribute to the development of novel antimalarial therapies. -
Parasite Inhibitor
BiPNQ is a potent inhibitor of Trypanosoma cruzi, the protozoan responsible for Chagas disease. This compound effectively disrupts the biological processes of the parasite, making it a valuable tool for research focused on the treatment of Chagas disease and the development of antiparasitic therapies. Its inhibitory activity may help elucidate the mechanisms of infection and potential therapeutic targets. -
Parasite Inhibitor
Ludaconitine, derived from Aconitum spicatum (Bruhl) Stapf, functions as a potent inhibitor of parasites. It demonstrates significant antileishmanial activity, exhibiting an IC50 of 36.10 μg/mL. This compound is valuable for research applications focused on leishmaniasis and the exploration of novel antiparasitic agents. -
Parasite Inhibitor
Ep vinyl quinidine, an epi-vinyl stereoisomer of Quinidine, serves as a targeted inhibitor of parasitic activity. This compound exhibits significant potential in malaria research, leveraging its capabilities as a selective cytochrome P450db inhibitor. Additionally, it functions as a potassium channel blocker with an IC50 of 19.9 μM, positioning it as a valuable tool for investigating anti-parasitic mechanisms and therapeutic interventions. -
Parasite Inhibitor
Antileishmanial agent-1 specifically targets Leishmania parasites, demonstrating potent inhibitory activity against L. amazonensis promastigotes with an IC50 of 15.52 μM and intracellular amastigotes with an IC50 of 4.10 μM. This compound is valuable for research focused on leishmaniasis treatment, facilitating studies on parasite bioenergetics and drug resistance mechanisms. Its ability to effectively inhibit parasite growth makes it a significant tool in the development of antileishmanial therapies. -
Parasite Inhibitor
Melilotigenin C is a natural product derived from the genus Erythrina, primarily acting as a parasite inhibitor. It exhibits significant antiplasmodial activity, making it a candidate for studies focused on malaria treatment. Additionally, Melilotigenin C demonstrates antimycobacterial properties and presents potential for cytotoxicity research, contributing to the exploration of new therapeutic agents against infectious diseases. -
Parasite Ubiquinol Oxidation Site Inhibitor
ELQ-121 is a potent inhibitor targeting the ubiquinol oxidation site in parasites. It exhibits remarkable antimalarial activity, with an IC50 of 0.05 nM against both chloroquine-sensitive and multidrug-resistant strains of P. falciparum in vitro. Additionally, ELQ-121 demonstrates high efficacy against T. gondii and N. caninum, with IC50 values below 1 nM, and suppresses B. besnoiti tachyzoite proliferation with an IC50 of 0.49 nM, accompanied by mitochondrial disruption. Furthermore, the compound can be formulated as a polyethylene glycol carbonate ester prodrug, showing in vivo efficacy against P. yoelii in mice, making it a valuable tool for antimalarial research. -
Parasite Inhibitor
BRD5018 is a selective antimalarial agent that targets Plasmodium parasites. This compound functions as a click chemistry reagent, featuring an alkyne group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc). Its ability to facilitate this reaction expands its utility in chemical biology applications, particularly in the development of novel therapeutic strategies against malaria. -
Parasite Inhibitor
Antimalarial agent 2 is a novel compound that targets Plasmodium parasites, displaying a rapid in vitro killing profile. This reagent demonstrates potent antiparasitic activity, making it a valuable tool for research into malaria treatment and the development of effective antimalarial therapies. Its oral efficacy indicates potential for further exploration in therapeutic applications against malaria. -
Parasite Inhibitor
Carbarsone, or p-ureidobenzenearsonic acid, primarily functions as a parasite inhibitor with notable efficacy as an amebicide. Historically utilized in human and veterinary medicine, it has been incorporated into poultry and swine feed to mitigate conditions such as blackhead in turkeys, often in conjunction with antibiotics. Its relatively low acute toxicity has prompted research into its safety as a food additive, with studies indicating minimal carcinogenic risk under chronic ingestion, similar to other arsanilic acid derivatives. Carbarsone is metabolized to arsanilic acid, which has been investigated in high-dose studies in canine models. -
Parasite Inhibitor
MMV666810 is a potent parasite inhibitor that targets asexual stages of parasites, exhibiting an IC50 of 5.94 nM. Notably, it demonstrates a 3.3-fold selectivity for late-stage gametocytes over earlier stages, with IC50 values of 179 ± 8 nM for late-stage and 603 ± 88 nM for early-stage gametocytes. This compound is valuable for research applications focused on antimalarial drug development and understanding gametocyte biology. -
Parasite Inhibitor
3-ANOT is a metabolite of Dinitolmide, functioning primarily as a parasite inhibitor. It demonstrates significant efficacy against coccidia, making it essential for research into antiparasitic mechanisms. 3-ANOT is applicable in studies focused on the prevention and treatment of parasitic infections in livestock, especially in poultry. -
Parasite Inhibitor
IWY357 is a potent inhibitor of Plasmodium falciparum, specifically targeting the blood stage of the parasite. This compound exhibits significant efficacy in disrupting the life cycle of the parasite, making it a valuable tool for researchers investigating malaria infection mechanisms and developing therapeutic strategies. Its long-acting properties can contribute to the understanding of parasite biology and assist in the design of novel anti-malarial drugs. -
Parasite Inhibitor
Nopol is a quinoline derivative that acts as a potent inhibitor of the asexual blood stage of Plasmodium falciparum. Its structural variations result in differing biological activities against various Plasmodium strains, with certain derivatives exhibiting submicromolar EC50 values for specific strains. This compound is valuable for research focused on malaria treatment and the development of antimalarial agents. -
Parasite Inhibitor
Phebestin is a compound that exhibits potent antimalarial activity by inhibiting the growth of Plasmodium spp. It demonstrates significant efficacy in both in vitro and in vivo studies. Additionally, Phebestin interacts with key enzymes associated with the Plasmodium life cycle, making it a valuable tool for research in parasitology and the development of novel antimalarial therapies. -
Parasite Inhibitor
M&B 5124 is a potent inhibitor targeting Schistosoma mansoni, a pathogenic trematode responsible for schistosomiasis. This compound demonstrates significant antiparasitic activity in murine models, making it a valuable tool for research into therapeutic strategies against schistosomiasis. Its efficacy positions it as a candidate for further studies aimed at understanding parasitic infections and developing new treatment options. -
Parasite Inhibitor
Melarsonyl dipotassium is a potent anthelmintic agent that targets various parasitic organisms. By interfering with metabolic processes in parasites, it exhibits significant inhibitory activity, making it valuable for research in parasitology and drug development. This compound is particularly relevant in studying the mechanisms of anthelmintic resistance and developing novel therapeutic strategies against parasitic infections. -
Parasite Inhibitor
trans-Cinnamic anhydride is a parasite inhibitor with a primary target of Plasmodium falciparum. This compound, isolated from Cinnamomum zeylanicum, demonstrates moderate antimalarial activity. It is utilized in pharmacological studies aimed at developing therapeutic agents against parasitic infections. -
Parasite Inhibitor
Epsiprantel is a potent anti-Echinococcus compound that functions as a parasite inhibitor, effectively inducing the death of protoscolex, larvae, and adult stages of the parasite in vitro. In vivo studies demonstrate its higher efficacy against mature worms compared to larvae, making it a valuable tool for research into Echinococcus infections and potential therapeutic strategies. Epsiprantel is characterized by its safety profile, showing no adverse side effects in tested models. -
Parasite Inhibitor
6-O-Methacrylate is a trilobolide derivative derived from the leaves of Wedelia trilobata, functioning primarily as a parasite inhibitor. It exhibits significant antimalarial activity with an IC50 of 8.9 μg/mL against the Plasmodium falciparum parasite. Additionally, 6-O-Methacrylate demonstrates antiviral properties by inhibiting the tobacco mosaic virus (TMV). This compound is valuable for research in parasitology and virology. -
Parasite Inhibitor
Cyclobendazole is a benzimidazole derivative targeting protozoan parasites. It demonstrates potent in vitro activity against Trichomonas vaginalis and Giardia lamblia, with IC50 values of 1.1 μg/mL and 0.047 μg/mL, respectively. This compound is useful in research applications focused on combating protozoal infections and studying their biological pathways. -
Parasite Inhibitor
Fenbendazole sulfone is a benzimidazole anthelmintic agent that acts as a parasite inhibitor. It is a minor metabolite of fenbendazole, demonstrating significant activity against various helminths. This compound is primarily utilized in research focused on parasitic infections and anthelmintic drug development. -
Parasite Inhibitor
Anti-infective agent 9 is an inhibitor of Plasmodium falciparum, exhibiting an IC50 of 600 nM, which targets metabolic pathways by downregulating pyruvate levels and interfering with the TCA cycle. This compound demonstrates favorable metabolic stability and low toxicity in human liver cells, making it a viable candidate for further research into antimalarial therapies. Additionally, studies suggest that its mechanism of action may involve pathways beyond 1-deoxy-D-xylulose-5-phosphate synthase (DXPS), highlighting its potential as a multifaceted therapeutic agent in combating malaria. -
Parasite Inhibitor
Lettowienolide is a geranylbenzoquinonoid that targets the Plasmodium falciparum malaria parasite. It demonstrates mild in vitro inhibitory activity, with an IC50 of approximately 20 μg/mL. This compound is relevant for research applications focusing on malaria treatment and the exploration of new therapeutic agents against parasitic infections. -
Parasite Inhibitor
Amabiline is a natural compound derived from specific plant sources, exhibiting potent activity as a parasite inhibitor. It demonstrates notable biological effects that make it valuable for research involving parasitic infections. Amabiline’s unique pharmacological properties may also provide insights into potential therapeutic applications, while its safety profile warrants consideration in various experimental contexts. -
Parasite Inhibitor
Antimalarial Agent 3 is a potent parasite inhibitor that exhibits nanomolar antiplasmodial activity, with an IC50 value of 0.035 μM. This compound demonstrates a high selectivity index, indicating minimal toxicity to mammalian cells. Its effectiveness makes it a valuable tool for research focused on developing antimalarial therapies and understanding parasite biology. -
Parasite Inhibitor
LAPTc-IN-1 is a competitive inhibitor of acidic M17 leucinopeptidase (LAPTc), exhibiting a Ki value of 0.27 μM. This compound demonstrates potent antagonistic activity against the parasite Trypanosoma cruzi, making it a valuable tool for research into parasitic infections. Its specificity towards LAPTc positions it as a potential candidate for the development of therapeutic strategies targeting Chagas disease and other related conditions. -
Parasite Inhibitor
Linearolactone is a compound that exhibits potent anti-Giardia activity, primarily targeting Giardia trophozoites. It induces necrotic cell death in these parasites, which can be attributed to its interaction with a predicted target protein. This compound is valuable for research applications focused on parasitic infections and the development of new therapeutic strategies against Giardia. -
Parasite Inhibitor
Anti-parasitic agent 3 is a potent inhibitor targeting resistant parasites, exhibiting significant anti-parasitic activity. This compound is essential for research applications focused on parasitic infections and the development of effective treatments. Its mechanism of action provides valuable insights into overcoming resistance in various parasitic species. -
Parasite Inhibitor
SSJ-183 is a parasite inhibitor with notable antimalarial activity. It functions by modulating both the efficacy and pharmacokinetic properties relevant to antimalarial treatment. Studies have demonstrated its potential in antimalarial research, positioning SSJ-183 as a significant candidate for the development of new combination therapies targeting malaria. -
Parasite Inhibitor
GSK932121 is a selective antimalarial agent that targets the electron transport chain of Plasmodium falciparum by inhibiting cytochrome bc1 (complex III). This compound disrupts the parasite's metabolic processes, demonstrating significant activity against malaria. Due to its efficient five-step synthesis process, GSK932121 can be produced at kilogram scale, making it suitable for extensive clinical research applications. -
Parasite Inhibitor
MMV674850 is a potent inhibitor targeting asexual stage parasites, exhibiting IC50 values of 2.7 and 4.5 nM. This compound preferentially affects early-stage gametocytes, with an IC50 of 4.5 ± 3.6 nM, while late-stage gametocytes display an IC50 of 28.7 ± 0.2 nM. MMV674850 serves as a valuable tool for research focused on malaria and parasite biology, particularly in investigating gametocyte development and inhibition strategies. -
Parasite Inhibitor
PfPKG-IN-1 is an imidazole-based inhibitor targeting Plasmodium falciparum cGMP-dependent protein kinase (PfPKG). This compound exhibits significant biological activity by interfering with the function of PfPKG, an essential enzyme in the life cycle of the malaria parasite. PfPKG-IN-1 is utilized in research applications aimed at developing effective antimalarial therapies and understanding the molecular mechanisms of parasite survival and replication. -
Parasite Inhibitor
6-Benzylthioinosine acts as a potent inhibitor of parasite growth, demonstrating significant antileukemic activity by enhancing cytotoxic effects against acute myeloid leukemia cells. It operates by modulating cellular metabolism and influencing signaling pathways, particularly when used in combination with metformin. This compound is valuable for research applications focused on leukemia treatment and understanding metabolic regulation in cancer. -
Parasite Inhibitor
Antileishmanial agent-2 is a potent inhibitor targeting Leishmania parasites, demonstrating submicromolar antileishmanial activity with an IC50 value of 0.29 μM. This compound exhibits a high selectivity index, indicating minimal toxicity to mammalian cells. It is suitable for research applications focused on the development of therapies for leishmaniasis and related parasitic infections. -
Parasite Inhibitor
(+)-Isopulegol functions primarily as a parasite inhibitor, derived from the terpenoid constituents of Mentha canadensis L. It exhibits phagostimulatory effects on adult pests, particularly S. granarius and T. confusum, acting as a feeding attractant for adult T. confusum and larvae of T. granarium. This compound is valuable for research applications in pest control and management strategies targeting stored product insects.

